Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Taxes (2020 - 2023)

Cytek Biosciences (CTKB) has disclosed Current Taxes for 3 consecutive years, with $1.3 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Current Taxes changed N/A year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Mar 2022, changed N/A, and an annual FY2021 reading of $1.4 million, up 147.88% over the prior year.
  • Current Taxes was $1.3 million for Q1 2022 at Cytek Biosciences, down from $1.4 million in the prior quarter.
  • Across five years, Current Taxes topped out at $1.4 million in Q4 2021 and bottomed at $566000.0 in Q4 2020.
  • Average Current Taxes over 3 years is $984750.0, with a median of $985000.0 recorded in 2021.
  • Peak annual rise in Current Taxes hit 147.88% in 2021, while the deepest fall reached 147.88% in 2021.
  • Year by year, Current Taxes stood at $566000.0 in 2020, then surged by 147.88% to $1.4 million in 2021, then dropped by 5.84% to $1.3 million in 2022.
  • Business Quant data shows Current Taxes for CTKB at $1.3 million in Q1 2022, $1.4 million in Q4 2021, and $649000.0 in Q3 2021.